<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724384</url>
  </required_header>
  <id_info>
    <org_study_id>OM-0030</org_study_id>
    <nct_id>NCT02724384</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety, Tolerability and Preliminary Efficacy of Plasma in Improving the Appearance of Onychomycosis</brief_title>
  <official_title>A Multi-Center Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Improving the Appearance of Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moe Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moe Medical Devices</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and preliminary efficacy of using&#xD;
      electrical plasma to treat toenail fungus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      75 patients will be recruited at several sites. Patients will be split into 3 groups that&#xD;
      have different treatment doses. Patient participation in the study will last 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective of this study is to compare the short-term safety and tolerability of application of non-ablative electrical plasma to human nails among the different dosing regimes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as assessed by Clinical, Mycological and Complete Cure Rates assessed in accordance with FDA Guidance for onychomycosis trials issued March 7, 2016</measure>
    <time_frame>12 months</time_frame>
    <description>The secondary objective of this study is to evaluate the preliminary efficacy of non-ablative electrical plasma in improving the appearance and treatment of onychomycosis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma treatment using Plasma delivery system A 3 treatments/week for 2 weeks, then monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma treatment using Plasma delivery system A 2 treatments/week for 2 weeks, then monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma treatment using Plasma delivery system B 3 treatments/week for 2 weeks, then monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MOE Plasma Delivery System A</intervention_name>
    <description>Plasma treatment</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MOE Plasma Delivery System B</intervention_name>
    <description>Plasma treatment</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be between 18 and 70 years of age inclusive, of either sex, and of any&#xD;
             race;&#xD;
&#xD;
          2. Subject must have distal subungual infection that affects approximately 25% to 60% of&#xD;
             at least one great toenail&#xD;
&#xD;
          3. Dermatophyte infection or infection with C. Albicans in the target great toenail&#xD;
             confirmed by identification of a dermatophyte organism in culture;&#xD;
&#xD;
          4. Subject must have at least 3 mm from the proximal end of the target toenail free of&#xD;
             infection;&#xD;
&#xD;
          5. Subject must have a target toenail that is assessed as capable of growing&#xD;
             approximately 1 mm/month, (e.g., the subject needs to report cutting his or her&#xD;
             toenails at least once per month);&#xD;
&#xD;
          6. Subject must be willing to give written informed consent and able to adhere to&#xD;
             procedures and visit schedules;&#xD;
&#xD;
          7. Subject must consent to having the toenails photographed during the study period;&#xD;
&#xD;
          8. Woman of childbearing potential: If currently sexually active, must agree to use a&#xD;
             medically accepted method of contraception while receiving protocol-specified&#xD;
             medication and for 30 days after stopping the study treatments; If not currently&#xD;
             active, must agree to use medically accepted method of contraception should she become&#xD;
             sexually active during study participation. Methods include condoms (male or female)&#xD;
             with or without a spermicidal agent, diaphragm or cervical cap with spermicide,&#xD;
             medically prescribed intrauterine device, oral or systemic hormonal contraceptive&#xD;
             (plus an additional reliable barrier method), and surgical sterilization (e.g.,&#xD;
             hysterectomy or tubal ligation);&#xD;
&#xD;
          9. Woman of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             prior to start of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with more than 6 infected toenails&#xD;
&#xD;
          2. Subject with fingernail onychomycosis&#xD;
&#xD;
          3. Subject with one or more of the following conditions on the primary target toenail:&#xD;
&#xD;
               1. white superficial onychomycosis&#xD;
&#xD;
               2. dermatophytoma or &quot;yellow spike/streak&quot;&#xD;
&#xD;
               3. primarily lateral or bi-lateral disease&#xD;
&#xD;
               4. toenail thickness greater than 3 mm&#xD;
&#xD;
               5. inability to become normal in the opinion of the investigator&#xD;
&#xD;
          4. Subject with psoriasis, pincer nail, prior nail surgery, severe moccasin-type tinea&#xD;
             pedis requiring treatment, symptomatic interdigital tinea pedis, lichen planus, or&#xD;
             other abnormalities that could result in a clinically abnormal nail;&#xD;
&#xD;
          5. Subject with peripheral vascular disease or peripheral circulatory impairment;&#xD;
&#xD;
          6. Subject with uncontrolled diabetes mellitus, subjects with diabetes controlled by&#xD;
             insulin or with known diabetic peripheral neuropathy&#xD;
&#xD;
          7. Subject with any known immunodeficiency;&#xD;
&#xD;
          8. Any pacemakers, or any metallic implants or prostheses in the vicinity of the&#xD;
             treatment site (such as ankle, foot, etc.);&#xD;
&#xD;
          9. Subject with any clinically significant condition or situation, other than the&#xD;
             condition being studied that, in the opinion of the investigator, would interfere with&#xD;
             study evaluations or optimal participation in the study;&#xD;
&#xD;
         10. Subject who has received systemic antifungal therapy within 6 months (except single&#xD;
             diflucan tablet for vaginal candida) or topical antifungal therapy applied to the foot&#xD;
             or toenails within 1 month of study entry;&#xD;
&#xD;
         11. Subject who has received radiation therapy, chemotherapy, and/or immunosuppressive&#xD;
             drugs within 6 months of study, and/or oral corticosteroids for &gt;1 month within the 6&#xD;
             months of study (exception: inhaled steroids);&#xD;
&#xD;
         12. Subject known to have received treatment with investigational drugs or devices within&#xD;
             30 days prior to enrollment into this study;&#xD;
&#xD;
         13. Subject who is unwilling to abstain from any cosmetic nail or foot treatments outside&#xD;
             those provided by the study clinic, beyond basic nail trimming (i.e. no spa foot&#xD;
             treatments, no pedicures/toenail polish use, no other topical prescription toenail&#xD;
             medication);&#xD;
&#xD;
         14. Woman who is breastfeeding, pregnant, or intends to become pregnant (check via urine&#xD;
             test only);&#xD;
&#xD;
         15. Subject who is part of the staff personnel directly involved with this study or a&#xD;
             family member of the investigational study staff;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sin Park, PhD</last_name>
    <phone>914-594-1985</phone>
    <email>allsra@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MOE Medical Devices Site 5</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MOE Medical Devices Site 4</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>MOE Medical Devices Investigational Site 3</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>MOE Medical Devices Site 6</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janet DuBois</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MOE Medical Devices Investigational Site 1</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MOE Medical Devices Investigational Site 2</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MOE Medical Devices Site 7</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Pollak</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

